Mirum PharmaceuticalsMIRM

• Phase 2마랄릭시바트(MRX-901) 임신성 담즙정체증 임상시작 전MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)
  67%
• Phase 1방사성 표지 [14C]-MRM-3379 체내동태 연구모집 중A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379
  47%
• Phase 2D형 간염 치료제 브렐로비투그 전환 임상 2b/3상모집 중Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
  62%
• Phase 2원발성 담즙성 담관염 가려움증 치료제 볼릭시바트 임상모집 중A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
  0%
• Phase 3담즙정체성 간질환 가려움증 치료제 마랄릭시뱃 임상진행 중Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
  100%
• Phase 3만성 D형 간염 대상 브렐로비투그(BJT-778) 비교 임상모집 중A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
  68%
• Phase 3브렐로비투그 만성 델타형 간염 치료 임상모집 중A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
  62%
• Phase 2BJT-778 만성 D형 간염 치료 효과 비교 임상진행 중A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
  68%
• Phase 2원발성 경화성 담관염 가려움증 치료제 볼릭시바트 임상진행 중A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
  63%
• Phase ?리브말리 알라질 증후군 유럽 장기 치료 임상모집 중Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
  41%
• Phase ?희귀 간질환 치료제 리브말리 장기 안전성 연구모집 중Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
  83%
• Phase ?콜밤(담즙산 결핍 치료제) 환자 등록 연구진행 중The REPLACE Registry for Cholbam® (Cholic Acid)
  53%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.